Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments

Radiation Oncology

Luca Cozzi¹  Eugenio Vanetti¹  Angelo Tozzi²  Stefano Arcangeli²  Antonella Roggio²  Anna M Ascolese²  Giacomo Reggiori²  Sara Pentimalli²  Chiara Pellegrini²  Valentina Palumbo²  Pierina Navarria²  Pietro Mancosu²  Francesca Lobefalo²  Antonella Fogliata¹  Alessandro Clivio¹  Simona Castiglioni²  Filippo Alongi²  Marta Scorsetti² 

[1] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;Radiotherapy and radiosurgery, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano (Milano), Italy

关键词: TrueBeam;    RapidArc;    SBRT;    Flattening Filter Free;   

Others  :  1223902
DOI  :  10.1186/1748-717X-6-113

 received in 2011-07-05, accepted in 2011-09-12,  发布年份 2011

【 摘 要 】

Purpose

To test feasibility and safety of clinical usage of Flattening Filter Free (FFF) beams for delivering ablative stereotactic body radiation therapy (SBRT) doses to various tumor sites, by means of Varian TrueBeam™ (Varian Medical Systems).

Methods and Materials

Seventy patients were treated with SBRT and FFF: 51 lesions were in the thorax (48 patients),10 in the liver, 9 in isolated abdominal lymph node, adrenal gland or pancreas. Doses ranged from 32 to 75 Gy, depending on the anatomical site and the volume of the lesion to irradiate. Lung lesions were treated with cumulative doses of 32 or 48 Gy, delivered in 4 consecutive fractions. The liver patients were treated in 3 fractions with total dose of 75 Gy. The isolated lymph nodes were irradiated in 6 fractions with doses of 45 Gy. The inclusion criteria were the presence of isolated node, or few lymph nodes in the same lymph node region, in absence of other active sites of cancer disease before the SBRT treatment.

Results

All 70 patients completed the treatment. The minimum follow-up was 3 months. Six cases of acute toxicities were recorded (2 Grade2 and 2 Grade3 in lung and 2 Grade2 in abdomen). No patient experienced acute toxicity greater than Grade3. No other types or grades of toxicities were observed at clinical evaluation visits.

Conclusions

This study showed that, with respect to acute toxicity, SBRT with FFF beams showed to be a feasible technique in 70 consecutive patients with various primary and metastatic lesions in the body.

【 授权许可】

   
2011 Scorsetti et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Timmerman RD, Cho LC, et al.: JCO 2007 Stereotactic Body Radiation Therapy in Multiple Organ Sites. J Clin Oncol 2007, 25:947-952.
• [2]Timmerman R, Papiez L, McGarry R, et al.: Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 2003, 124:1946-1955.
• [3]Timmerman RD, McGarry R, Yiannoutsos C, et al.: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
• [4]Onishi H, Shirato H, Nagata Y, et al.: Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys 2010, in press.
• [5]Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13:8-10.
• [6]Wersall PJ, Blomgren H, Lax I, et al.: Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77:88-95.
• [7]Madsen BL, Hsi RA, Pham HT, et al.: Intrafractional stability of the prostate using a stereotactic radiotherapy technique. Int J Radiat Oncol Biol Phys 2003, 57:1285-1291.
• [8]Miralbell R, Molla M, Arnalte R, et al.: Target repositioning optimization in prostate cancer: Is intensity-modulated radiotherapy under stereotactic conditions feasible? Int J Radiat Oncol Biol Phys 2004, 59:366-371.
• [9]Wang L, Jacob R, Chen L, et al.: Stereotactic IMRT for prostate cancer: Setup accuracy of a new stereotactic body localization system. J Appl Clin Med Phys 2004, 5:18-28.
• [10]Hoyer M, Roed H, Sengelov L, et al.: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53.
• [11]Koong AC, Le QT, Ho A, et al.: Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58:1017-1021.
• [12]Koong AC, Christofferson E, Le QT, et al.: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320-323.
• [13]Rusthoven KE, Kavanagh BD, Cardenes H, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-8.
• [14]Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008, 35:310-317.
• [15]Bignardi M, Navarria P, Mancosu P, et al.: Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiati Oncol Biol Phys 2010, in press.
• [16]Bignardi M, Cozzi L, Fogliata A, et al.: Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009, 75:1570-1577.
• [17]Ong C, Palma D, Verbakel W, et al.: Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol 2010, 97:431-436.
• [18]Vassiliev O, Kry S, Kuban D, et al.: Treatment planning study of prostate cancer intensity modulated radiotherapy with a Varian clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys 2007, 68:1567-1571.
• [19]Poenisch F, Titt U, Vassiliev O, et al.: Properties of unflattened photon beams shaped by a multileaf collimator. Med Phys 2006, 33:1738-1746.
• [20]Vassiliev ON, Kry SF, Chang JY, et al.: Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 2009, 10:2880.
• [21]Cashmore J, Ramtohul M, Ford D: Lowering whole body radiation doses in pediatric intensity modulated radiotherapy through the use of unflattened photon beams. Int J Radiat oncol BIol Phys 2011, in press.
• [22]Georg D, Knoos T, McClean B: Current status and future perspective of flattening filter free photon beams. Med Phys 2011, 38:1280-1293.
• [23]Kragl G, Wetterstedt S, Knausl B, et al.: Dosimetric characteristics of 6 and 10 MV unflattened photon beams. Radiother Oncol 2009, 93:141-146.
• [24]Hrbacek J, Lang S, Kloeck S: Commissioning of photon beams of a flattening filter free linear accelerator and the accuracy of beam modeling using an anisotropic analytical algorithm. Int J Radiat oncol Biol Phys 2011, in press.
• [25]Scorsetti M, Fogliata A, Castiglioni S, et al.: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiat Oncol 2010, 5:93. BioMed Central Full Text
• [26]Scorsetti M, Navarria P, Mancosu P, et al.: Large volume unresectable locally advances non small cell lung cancer: acute toxicity and initial outcome results with RapidArc. Radiat Oncol 2010, 5:94. BioMed Central Full Text
• [27]Gwynne S, Wills L, Joseph G, John G, Hurt C, et al.: Respiratory Movement of Upper Abdominal Organs and its Effect on Radiotherapy Planning in Pancreatic Cancer. Clin Oncol 2009, 21:713-719.
• [28]Kubas A, Mornex F, Merle P, et al.: Irradiation of hepatocellular carcinoma: Impact of breathing on motions and variations of volume of the tumor, liver and upper abdominal organs. Cancer Radiother 2008, 12:768-774.
• [29]Dunlap N, Cai J, Beidermann G, et al.: Chest wall volume receiving > 30 Gy predicts risk of severe pain and or rib fracture after lung stereotactic body radiotherapy. Int J Radiat oncol Biol Phys 2009, 76:796-801.
• [30]Fogliata A, Clivio A, Nicolini G, et al.: Intensity modulation with photons for benign intracranial tumours. A planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 2008, 89:254-262.
• [31]Ulmer W, Pyyry J, Kaissl W: A 3D photon superposition convolution algorithm and its foundation on results of Monte Carlo calculations. Phys Med Biol 2005, 50:1767-90.
• [32]ICRU report 83: Prescribing, recording and reporting Intensity Modulated Photon Beam Therapy (IMRT) (ICRU report 83). Washington, DC: International Commission on Radiation Units and Measurements; 2010.
• [33]National Cancer Institute: Cancer Therapy Evaluation Program. [http://ctep.cancer.gov] webciteCommon Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, NHHS 2003.